FGFR Inhibitor RLY-4008 Shows Promise in Treating Metastatic CCA

Web Exclusives — December 7, 2022

RLY-4008 is an oral inhibitor of fibroblast growth factor 2 (FGFR2) currently under investigation to treat unresectable or metastatic cholangiocarcinoma (CCA) that has not responded to standard therapies. Previous studies of nonselective FGFR inhibitors have reinforced the use of fragmented and/or rearranged FGFR2 as a therapeutic target in patients with relevant CCA diagnoses. However, the efficacy of these nonselective FGFR inhibitors is limited by their significant off-target toxicity and the accumulation of FGFR resistance mutations in tumors over time.

The ReFocus (RLY-4008-101) clinical trial was a phase 1/2 nonrandomized parallel assignment study accepting patients with solid CCA tumors. Characterization of fragmented and/or rearranged FGFR2 was determined for each patient by local testing. Patients received oral RLY-4008 (doses ranged from 20 mg to 200 mg QD or BID). Primary objectives of this study included objective response rate (ORR) assessed per RECIST version 1.1 and duration of response (DOR) assessed up to 36 months following treatment. Safety and adverse events (AEs) were analyzed for all patients. Response was confirmed based on measurable disease and ≥2 tumor assessments.

Currently, 38 patients (all FGFR inhibitor-naïve with fragmented and/or rearranged FGFR2 ) have received treatment and were evaluable for ORR, DOR, and safety. Most patients received the recommended phase 2 dose (RP2D, 70 mg QD), and 68% of these remained on the treatment (median duration, 6 months).

RLY-4008 showed potent efficacy across all doses, with an ORR of 88% at RP2D. In the cohort treated with RP2D, 1 patient demonstrated a near-complete response and was able to undergo subsequent curative tumor resection. Data collection for DOR is thus far incomplete, and research is ongoing. Treatment-related AEs have been grade ≤3 in severity; low-grade stomatitis (48%), palmar plantar erythrodysesthesia (46%), and dry mouth (31%) were most commonly reported.

Preliminary findings indicated that RLY-4008 has significant promise as a next-generation FGFR2-specific inhibitor to treat metastatic CCA in patients with fragmented and/or rearranged FGFR2 who have not received other FGFR inhibitor therapeutics. Research on this medication continues in the ReFocus trial.

Source: Hollebecque A, Borad M, Goyal L, et al. Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial. Ann Oncol. 2022;33(suppl 7):S808-S869.

Related Items

The Impact of mFOLFOX Chemotherapy in Conjunction with Active Symptom Control on Patient QOL: The ABC-06 Trial
Web Exclusives
Preliminary analyses of patient quality-of-life data from the ABC-06 clinical trial suggest a potentially positive impact of L-folinic acid plus oxaliplatin plus 5-fluorouracil when used in conjunction with active symptom control.
Derazantinib Shows Clinical Efficacy in the Treatment of iCCA in Patients with Genetically Aberrant FGFR2
Web Exclusives
Data from the FIDES-01 clinical trial showed encouraging results for derazantinib as a second-line treatment for patients with intrahepatic cholangiocarcinoma with FGFR2 fusions, mutations, or amplification.
Real-World Evidence for Liquid Biopsy to Identify Molecular Alterations
Web Exclusives
Real-world evidence supports a role for liquid biopsy in identifying molecular alterations, offering personalized treatment options.
Nanoliposomal Irinotecan Combination Therapy Falls Short in Metastatic BTC
Web Exclusives
The NALIRICC study compared the efficacy of nanoliposomal irinotecan plus 5-fluorouracil (5-FU) plus leucovorin (LV) with 5-FU plus LV on progression-free and overall survival in patients with biliary tract cancer.
Tislelizumab as Part of a Conversion Therapy Regimen for Potentially Resectable Biliary Tract Cancers
Web Exclusives
A phase 2 study found that the combination of tislelizumab, lenvatinib, and gemcitabine/oxaliplatin showed promise as a conversion therapy for patients with potentially resectable locally advanced biliary tract cancer, making curative surgery a possibility for some patients.
Additional 6-Month Follow-up from the TOPAZ-1 Study Comparing Durvalumab with Placebo plus Gem/Cis in Patients with Advanced BTC
Web Exclusives
Updated overall survival (OS) and safety data from the TOPAZ-1 study revealed improved median OS for the full patient population as well as subgroup analyses and an adverse event profile consistent with previously reported data.
Immune-Related Adverse Events in the TOPAZ-1 Study of Durvalumab or Placebo plus GemCis in Advanced BTC
Web Exclusives
Analysis of the safety population in the TOPAZ-1 trial in patients with biliary tract cancer revealed that immune-related adverse events were more common in the durvalumab arm, had a variable time to onset, and were associated with improved overall survival.
CCA Summit Live from ESMO 2022
By Juan W. Valle, MB ChB, MSc, FRCP
On September 21, 2022, I presented an overview of key abstracts on biliary tract cancer (BTC) presented at the 2022 annual meeting of the European Society for Medical Oncology. In addition, I provided my perspective on the impact of the data on the management of patients with BTC.
Key Abstracts Presented at the European Society for Medical Oncology (ESMO) 2021 Annual Meeting
By Richard Kim, MD
Richard Kim, MD, from the Moffitt Cancer Center, University of South Florida College of Medicine, provides expert commentary on key abstracts and posters presented at the 2021 annual meeting of the European Society for Medical Oncology. Dr Kim will highlight new data from 11 presentations on interventional modalities for patients with cholangiocarcinoma.
Futibatinib Safe and Effective in Patients with Advanced or Metastatic Intrahepatic Cholangiocarcinoma and FGFR2 Fusions
October 2020, Vol 1, No 2
Two phase 2 studies of futibatinib, a highly selective irreversible fibroblast growth factor receptor (FGFR)1-4 inhibitor, analyzed data from the FOENIX-CCA2 clinical trial and were presented at the 2020 virtual meeting of the European Society for Medical Oncology (ESMO).

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: